Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Risk-Adapted Therapy for HIV-Associated Anal Cancer

NCT04929028 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT04929028
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04929028 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Risk-Adapted Therapy for HIV-Associated Anal Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 9, 2022
Completion date
September 15, 2031
Enrollment
40 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

aids-related anal carcinoma, anal margin squamous cell carcinoma, anal non-keratinizing squamous cell carcinoma, anal squamous cell carcinoma, hiv infection, rectal squamous cell carcinoma, stage ii rectal cancer ajcc v8, stage iib anal cancer ajcc v8, stage iii anal cancer ajcc v8, stage iii rectal cancer ajcc v8